Related references
Note: Only part of the references are listed.Dose-densified chemoimmunotherapy followed by systemic central nervous system prophylaxis for younger high-risk diffuse large B-cell/follicular grade 3 lymphoma patients: results of a phase II Nordic Lymphoma Group study
H. Holte et al.
ANNALS OF ONCOLOGY (2013)
Mutational and structural analysis of diffuse large B-cell lymphoma using whole-genome sequencing
Ryan D. Morin et al.
BLOOD (2013)
Pathogenesis of Human B Cell Lymphomas
Arthur L. Shaffer et al.
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30 (2012)
Integrative Analysis Reveals an Outcome-Associated and Targetable Pattern of p53 and Cell Cycle Deregulation in Diffuse Large B Cell Lymphoma
Stefano Monti et al.
CANCER CELL (2012)
Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing
Jens G. Lohr et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma
Ryan D. Morin et al.
NATURE (2011)
Global quantification of mammalian gene expression control
Bjoern Schwanhaeusser et al.
NATURE (2011)
Analysis of the coding genome of diffuse large B-cell lymphoma
Laura Pasqualucci et al.
NATURE GENETICS (2011)
Comprehensive exon array data processing method for quantitative analysis of alternative spliced variants
Ping Chen et al.
NUCLEIC ACIDS RESEARCH (2011)
COMMD1-Mediated Ubiquitination Regulates CFTR Trafficking
Loic Drevillon et al.
PLOS ONE (2011)
High resolution array comparative genomic hybridization identifies copy number alterations in diffuse large B-cell lymphoma that predict response to immuno-chemotherapy
F. Kreisel et al.
CANCER GENETICS (2011)
Diffuse large B-cell lymphomas with CDKN2A deletion have a distinct gene expression signature and a poor prognosis under R-CHOP treatment: a GELA study
Fabrice Jardin et al.
BLOOD (2010)
Nucleolar Targeting of RelA(p65) Is Regulated by COMMD1-Dependent Ubiquitination
Hazel C. Thoms et al.
CANCER RESEARCH (2010)
COMMD1 disrupts HIF-1 alpha/beta dimerization and inhibits human tumor cell invasion
Bart van de Sluis et al.
JOURNAL OF CLINICAL INVESTIGATION (2010)
Mechanisms of Disease: Aggressive Lymphomas.
Georg Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Large-scale data integration framework provides a comprehensive view on glioblastoma multiforme
Kristian Ovaska et al.
GENOME MEDICINE (2010)
COMMD1 expression is controlled by critical residues that determine XIAP binding
Gabriel N. Maine et al.
BIOCHEMICAL JOURNAL (2009)
Array Comparative Genomic Hybridization Identifies Genetic Regions Associated With Outcome in Aggressive Diffuse Large B-Cell Lymphomas
Cristina Robledo et al.
CANCER (2009)
The potential of copy number gains and losses, detected by array-based comparative genomic hybridization, for computational differential diagnosis of B-cell lymphomas and genetic regions involved in lymphomagenesis
Ichiro Takeuchi et al.
Haematologica-The Hematology Journal (2009)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas:: a randomised controlled trial (RICOVER-60)
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2008)
Stromal Gene Signatures in Large-B-Cell Lymphomas
G. Lenz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways
Georg Lenz et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
COMMD proteins: COMMing to the scene
G. N. Maine et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2007)
COMMD proteins and the control of the NFκB pathway
Gabriel N. Maine et al.
CELL CYCLE (2007)
Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma
Thomas M. Habermann et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Characterization of target genes at the 2p15-16 amplicon in diffuse large B-cell lymphoma
Noriko Fukuhara et al.
CANCER SCIENCE (2006)
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma:: a randomised controlled trial by the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2006)
Diffuse large B-cell lymphoma subgroups have distinct genetic profiles that influence tumor biology and improve gene-expression-based survival prediction
S Bea et al.
BLOOD (2005)
Comparison of genome profiles for identification of distinct subgroups of diffuse large B-cell lymphoma
H Tagawa et al.
BLOOD (2005)
Relationship between REL amplification, REL function, and clinical and biologic features in diffuse large B-cell lymphomas
J Houldsworth et al.
BLOOD (2004)
Detection of large-scale variation in the human genome
AJ Iafrate et al.
NATURE GENETICS (2004)
Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas:: results of the NHL-B1 trial of the DSHNHL
M Pfreundschuh et al.
BLOOD (2004)
Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression
DR Rhodes et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray
CP Hans et al.
BLOOD (2004)
Circular binary segmentation for the analysis of array-based DNA copy number data
AB Olshen et al.
BIOSTATISTICS (2004)
Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma
A Rosenwald et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma
G Wright et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma
A Rosenwald et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
The t(14;18) defines a unique subset of diffuse large B-cell lymphoma with a germinal center B-cell gene expression profile
JZ Huang et al.
BLOOD (2002)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning
MA Shipp et al.
NATURE MEDICINE (2002)
Multiclass cancer diagnosis using tumor gene expression signatures
S Ramaswamy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
Constitutive nuclear factor κB activity is required for survival of activated B cell-like diffuse large B cell lymphoma cells
RE Davis et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2001)
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling
AA Alizadeh et al.
NATURE (2000)
Share Paper
